Last reviewed · How we verify
High-dose ferric derisomaltose
High-dose ferric derisomaltose delivers iron directly to iron-deficient patients via a stable iron-carbohydrate complex that is absorbed and utilized for hemoglobin synthesis.
High-dose ferric derisomaltose delivers iron directly to iron-deficient patients via a stable iron-carbohydrate complex that is absorbed and utilized for hemoglobin synthesis. Used for Iron deficiency anemia.
At a glance
| Generic name | High-dose ferric derisomaltose |
|---|---|
| Also known as | More intensive target |
| Sponsor | China-Japan Friendship Hospital |
| Drug class | Iron replacement agent |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Ferric derisomaltose is an iron(III) carbohydrate complex designed for intravenous administration in iron deficiency anemia. The derisomaltose ligand stabilizes the iron core, allowing controlled release and absorption of iron in the body. This bypasses oral absorption limitations and enables rapid repletion of iron stores and hemoglobin production.
Approved indications
- Iron deficiency anemia
Common side effects
- Injection site reactions
- Nausea
- Headache
- Dizziness
Key clinical trials
- Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
- The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency (PHASE4)
- A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery (PHASE4)
- High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose ferric derisomaltose CI brief — competitive landscape report
- High-dose ferric derisomaltose updates RSS · CI watch RSS
- China-Japan Friendship Hospital portfolio CI